1. Home
  2. ATYR vs NYXH Comparison

ATYR vs NYXH Comparison

Compare ATYR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • NYXH
  • Stock Information
  • Founded
  • ATYR 2005
  • NYXH 2009
  • Country
  • ATYR United States
  • NYXH Belgium
  • Employees
  • ATYR N/A
  • NYXH N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • NYXH Medical/Dental Instruments
  • Sector
  • ATYR Health Care
  • NYXH Health Care
  • Exchange
  • ATYR Nasdaq
  • NYXH Nasdaq
  • Market Cap
  • ATYR 228.1M
  • NYXH 261.1M
  • IPO Year
  • ATYR 2015
  • NYXH 2021
  • Fundamental
  • Price
  • ATYR $3.30
  • NYXH $8.01
  • Analyst Decision
  • ATYR Strong Buy
  • NYXH Strong Buy
  • Analyst Count
  • ATYR 4
  • NYXH 5
  • Target Price
  • ATYR $19.25
  • NYXH $17.00
  • AVG Volume (30 Days)
  • ATYR 832.1K
  • NYXH 44.5K
  • Earning Date
  • ATYR 11-07-2024
  • NYXH 11-06-2024
  • Dividend Yield
  • ATYR N/A
  • NYXH N/A
  • EPS Growth
  • ATYR N/A
  • NYXH N/A
  • EPS
  • ATYR N/A
  • NYXH N/A
  • Revenue
  • ATYR $235,000.00
  • NYXH $5,668,079.00
  • Revenue This Year
  • ATYR N/A
  • NYXH $37.10
  • Revenue Next Year
  • ATYR $1,200.54
  • NYXH $418.12
  • P/E Ratio
  • ATYR N/A
  • NYXH N/A
  • Revenue Growth
  • ATYR N/A
  • NYXH 32.65
  • 52 Week Low
  • ATYR $1.34
  • NYXH $4.00
  • 52 Week High
  • ATYR $3.80
  • NYXH $20.00
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 52.43
  • NYXH 43.45
  • Support Level
  • ATYR $3.05
  • NYXH $7.74
  • Resistance Level
  • ATYR $3.26
  • NYXH $8.45
  • Average True Range (ATR)
  • ATYR 0.22
  • NYXH 0.47
  • MACD
  • ATYR -0.03
  • NYXH 0.06
  • Stochastic Oscillator
  • ATYR 30.00
  • NYXH 45.81

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: